Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays

Neutralizing antibody assays are powerful tools for assessing humoral immunity in AIDS virus infection and vaccine development. Although many different assays have been described, all are based on the same principle, measuring reductions in virus infectivity. This unit describes two assays utilizing a genetically engineered cell lines that are susceptible to infection by most strains of HIV‐1, SIV, and SHIV. One assay is designed for optimal performance with uncloned viruses produced in either PBMC or CD4+ T cell lines. A second assay is designed for single‐cycle infection with molecularly cloned pseudoviruses produced by transfection in 293T cells. Both assays are performed in a 96‐well format and use tat‐responsive luciferase reporter gene expression as readout.

[1]  A. Trkola,et al.  A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. , 2001, Virology.

[2]  D. Montefiori,et al.  Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.

[3]  C. Barbas,et al.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.

[4]  Ying Sun,et al.  Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection , 1997, The Journal of experimental medicine.

[5]  D. Montefiori.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection , 2004, Springer Seminars in Immunopathology.

[6]  M. Gonda,et al.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. , 1987, AIDS research and human retroviruses.

[7]  M. Tremblay,et al.  The acquisition of host-encoded proteins by nascent HIV-1. , 1998, Immunology today.

[8]  D. Littman,et al.  G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models. , 1998, Seminars in immunology.

[9]  D. Montefiori,et al.  Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. , 1994, Virology.

[10]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[11]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.

[12]  J. Mascola.  Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Infectivity Reduction Method. , 1999, Methods in molecular medicine.

[13]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[14]  D. Montefiori,et al.  Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay , 1988, Journal of clinical microbiology.

[15]  P. Cresswell,et al.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids , 2004, Immunogenetics.

[16]  D. Montefiori,et al.  Prospects for vaccine protection against HIV-1 infection and AIDS. , 2002, Annual review of immunology.

[17]  B. Chesebro,et al.  Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[18]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[19]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Hope,et al.  Association of Chemokine-mediated Block to HIV Entry with Coreceptor Internalization* , 2002, The Journal of Biological Chemistry.

[21]  D. Katzenstein,et al.  International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus. , 1990, AIDS research and human retroviruses.

[22]  L. Montagnier,et al.  A rapid and simple colorimetric test for the study of anti-HIV agents. , 1988, AIDS research and human retroviruses.

[23]  John R Mascola,et al.  Defining the protective antibody response for HIV-1. , 2003, Current molecular medicine.

[24]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[25]  J. Mascola.  Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Antibody Dilution Method. , 1999, Methods in molecular medicine.

[26]  H. Sheppard,et al.  Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers , 1990, Journal of clinical microbiology.

[27]  J. Hoxie,et al.  Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage , 1998, Journal of Virology.

[28]  David L. Robertson,et al.  HIV-1 nomenclature proposal: a reference guide to HIV-1 classification. , 2000 .

[29]  J. Mascola,et al.  Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. , 1993, AIDS research and human retroviruses.

[30]  J. Mascola,et al.  HIV-1: nature's master of disguise , 2003, Nature Medicine.